Evidence map›Paper›PMID 38009775›Full record

ReviewCancer biology & medicine2023

Targeting the mechano-microenvironment and liver cancer stem cells: a promising therapeutic strategy for liver cancer.

Xiaorong Fu, Yi Zhang, Qing Luo, Yang Ju, Guanbin Song

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer biology & medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaorong FuSchool of Biology and Engineering, Guizhou Medical University, Guiyang 550000, China.
Yi ZhangDepartment of Mechanical Science and Engineering, Nagoya University, Nagoya 4648603, Japan.
Qing LuoCollege of Bioengineering, Chongqing University, Chongqing 400030, China.
Yang JuDepartment of Mechanical Science and Engineering, Nagoya University, Nagoya 4648603, Japan.
Guanbin SongCollege of Bioengineering, Chongqing University, Chongqing 400030, China.ORCID 0000-0001-5217-0296

Funding

Japan Society for the Promotion of Science under grants-in-Aid for Scientific Research (S) 17H06146National Natural Science Foundation of China 11832008Natural Science Foundation Project of Chongqing cstc2020jcyj-msxmX0545
6 · The paper itself

Abstract

Over the past 2 decades, cancer stem cells (CSCs) have been identified as the root cause of cancer occurrence, progression, chemoradioresistance, recurrence, and metastasis. Targeting CSCs is a novel therapeutic strategy for cancer management and treatment. Liver cancer (LC) is a malignant disease that can endanger human health. Studies are increasingly suggesting that changes in the liver mechanical microenvironment are a primary driver triggering the occurrence and development of liver cancer. In this review, we summarize current understanding of the roles of the liver mechano-microenvironment and liver cancer stem cells (LCSCs) in liver cancer progression. We also discuss the relationship between the mechanical heterogeneity of liver cancer tissues and LCSC recruitment and metastasis. Finally, we highlight potential mechanosensitive molecules in LCSCs and mechanotherapy in liver cancer. Understanding the roles and regulatory mechanisms of the mechano-microenvironment and LCSCs may provide fundamental insights into liver cancer progression and aid in further development of novel therapeutic strategies.

Indexed as

Liver NeoplasmsHumansNeoplastic Stem CellsTumor Microenvironmentcancer stem cellsLiver cancermechano-microenvironmentmechanotherapytumor heterogeneity

Identifiers

PMID38009775
PMCPMC10690881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.